ICER says bluebird bio’s $2.1m gene therapy is cost-effective
pharmaphorum
APRIL 14, 2022
million price tag. ICER’s assessment is still at the draft stage and could be changed after an ongoing comment period, but will be welcomed by bluebird and other gene therapy developers as they try to set a price for their one-shot treatments that will be accepted by payers.
Let's personalize your content